Her 2Nib 250 MG Tablet contains Lapatinib 250 mg, a dual tyrosine kinase inhibitor used primarily in the treatment of HER2-positive breast cancer. Lapatinib selectively inhibits the intracellular tyrosine kinase domains of both the human epidermal growth factor receptor 2 (HER2/ErbB2) and epidermal growth factor receptor (EGFR/ErbB1), thereby blocking downstream signaling pathways involved in tumor cell proliferation and survival. This targeted therapy is indicated for patients with advanced or metastatic breast cancer that overexpresses the HER2 protein, often in combination with other chemotherapeutic agents such as capecitabine or letrozole. Her 2Nib 250 MG Tablet is administered orally, offering a convenient dosing regimen. Clinical studies have demonstrated its efficacy in improving progression-free survival and overall response rates in patients resistant to prior treatments like trastuzumab. Common adverse effects include diarrhea, rash, nausea, and fatigue, with serious but less frequent risks such as hepatotoxicity and cardiotoxicity requiring monitoring during therapy. Dose adjustments may be necessary in cases of hepatic impairment or adverse reactions. Her 2Nib 250 MG Tablet should be prescribed and monitored by oncology specialists familiar with HER2-targeted therapies to optimize patient outcomes.